Cancentus

Cancentus is a Swiss precision oncology biotechnology company focused on developing selective cancer therapies that exploit oncogene-induced DNA replication stress. A spin-off from the University of Geneva and the University of Basel, the company is advancing a pipeline that includes next-generation antibody-drug conjugate (ADC) payloads, selective helicase inhibitors, and synergistic combination therapies. Its lead program is a first-in-class ADC incorporating a novel checkpoint kinase 1 (CHK1) inhibitor payload designed to target cancer cells while sparing healthy tissue. In addition to its therapeutic pipeline, Cancentus leverages an AI-driven drug discovery (AIDD) platform to provide in-silico hit identification and lead optimization services.